Real world efficacy of naltrexone/bupropion for weight management in obesity and after bariatric surgery
Authors' conclusion
Real-world data show that NB treatment is equally effective in surgery-naive patients and in patients experiencing weight regain after bariatric surgery, regardless of the maximal dose administered.
Study context
- Population
- Patients with obesity started on naltrexone/bupropion (NB) after multidisciplinary consult, 2016–2022, surgery-naive or with weight regain/insufficient weight loss after metabolic and bariatric surgery (MBS); NB dose escalation up to 32/360 mg daily
- Participants
- 151 patients
- Exposure
- Naltrexone/bupropion in surgery-naive vs post-MBS patients
- Surgery-naiven = 111reference
- Post-MBSn = 40
- Outcome
- Weight loss
- Follow-up
- 12 months
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Continued NB use · 4 months
Continued NB use · 12 months
Median
| Outcome | Surgery-naive | Post-MBS |
|---|---|---|
| Weight loss · 4 months | 6.4% (IQR 3.0–10.1) | 6.3% (IQR 2.3–12.1) |
Effect of reaching maximal dose on weight loss
- Weight loss not significantly influenced by reaching maximal dose, surgery-naive
- P = 0.38
- Weight loss not significantly influenced by reaching maximal dose, post-MBS
- P = 0.72
Original publication
Real world efficacy of naltrexone/bupropion for weight management in obesity and after bariatric surgery. Int J Obes (Lond). Published 2 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →